128 related articles for article (PubMed ID: 2721537)
1. Cardiovascular regulation and lipoprotein profile during administration of co-dergocrine in essential hypertension.
Uehlinger DE; Weidmann P; Gnaedinger MP
Eur J Clin Pharmacol; 1989; 36(2):119-25. PubMed ID: 2721537
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular regulation during administration of co-dergocrine to normal subjects.
Gerber A; Weidmann P; Laederach K
Eur J Clin Pharmacol; 1986; 29(5):565-72. PubMed ID: 3956562
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and metabolic profile during intervention with urapidil in humans.
Gerber A; Weidmann P; Marone C; Uehlinger D; Riesen W
Hypertension; 1985; 7(6 Pt 1):963-71. PubMed ID: 3908316
[TBL] [Abstract][Full Text] [Related]
4. [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].
Mies R; Lang R; Weidinger G; Welzel D
Arzneimittelforschung; 1983; 33(5):771-3. PubMed ID: 6683557
[TBL] [Abstract][Full Text] [Related]
5. Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure.
Weidmann P; Schohn D; Gnädinger MP; Bürgisser E; Ferrier C; Jahn H
Am J Nephrol; 1989; 9(4):269-78. PubMed ID: 2683789
[TBL] [Abstract][Full Text] [Related]
6. Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine.
Marone C; Luisoli S; Bomio F; Beretta-Piccoli C; Bianchetti MG; Weidmann P
Kidney Int; 1985 Oct; 28(4):658-65. PubMed ID: 3910913
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
Beretta-Piccoli C; Ferrier C; Weidmann P
J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
[TBL] [Abstract][Full Text] [Related]
8. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
Woodcock BG; Herrmann W; Habedank WD
Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
[TBL] [Abstract][Full Text] [Related]
9. Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension.
Sánchez RA; Marcó E; Gilbert HB; Raffaele P; Brito M; Giménez M; Moledo LI
Drugs; 1985; 30 Suppl 1():49-58. PubMed ID: 2994987
[TBL] [Abstract][Full Text] [Related]
10. Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension.
Bianchetti MG; Weidmann P; Beretta-Piccoli C; Ferrier C
Kidney Int; 1987 Apr; 31(4):956-63. PubMed ID: 3586502
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
Clark BJ; Bucher T; Waite R
J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
[TBL] [Abstract][Full Text] [Related]
12. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
Collart F; Staroukine M; Verniory A
Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
14. Norepinephrine-related mechanism in hypertension accompanying renal failure.
Schohn D; Weidmann P; Jahn H; Beretta-Piccoli C
Kidney Int; 1985 Nov; 28(5):814-22. PubMed ID: 4087696
[TBL] [Abstract][Full Text] [Related]
15. Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.
Kirsten R; Nelson K; Weidinger G; Welzel D
Eur J Clin Pharmacol; 1990; 39(5):435-9. PubMed ID: 2076734
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.
Muiesan G; Alicandri CL; Agabiti-Rosei E; Fariello R; Beschi M; Boni E; Castellano M; Moniti E; Muiesan L; Romanelli G; Zanielli A
Am J Cardiol; 1982 Apr; 49(6):1420-4. PubMed ID: 6280474
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium.
Weidmann P; Beretta-Piccoli C; Meier A; Keusch G; Glück Z; Ziegler WH
Kidney Int; 1983 Feb; 23(2):320-6. PubMed ID: 6341684
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular counterregulation during sympathetic inhibition in normal subjects and patients with mild hypertension.
Weidmann P; Beretta-Piccoli C; Link L; Bianchetti MG; Boehringer K; Morton JJ
Hypertension; 1983; 5(6):873-80. PubMed ID: 6360870
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of verapamil in essential hypertension.
Städler P; Leonardi L; Riesen W; Ziegler W; Marone C; Beretta-Piccoli C
Clin Pharmacol Ther; 1987 Nov; 42(5):485-92. PubMed ID: 3315389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
